Arsenic, a toxic compound, has a significant positive effect on the survival of patients with acute leukaemia, scientists have found.
Wake Forest University Baptist Medical Center researchers conducted the study.
"Patients with APL can achieve remission with standard treatment (chemotherapy plus ATRA, an oral vitamin A-based compound), but it often comes back," said Bayard L. Powell.
"Arsenic trioxide is then used to get them back into remission, often followed by a bone marrow transplant to try to cure the patient. For this study, we used arsenic as an early "consolidation therapy" after the initial standard treatment to essentially, as one of our first patients described, 'seal the deal' the first time around. Not only did the leukemia rarely return in the patients who received the arsenic, those patients also lived longer," he said.
Acute promyelocytic leukemia (APL) is associated with a very high risk of severe bleeding complications, including early death from bleeding into the brain.
Those with high white blood cell counts at diagnosis have slimmer chances of complete remission. If they survive initial treatment and enter remission, they are also more prone to relapse, at which point arsenic is introduced to push them back into remission.